The next wave of radiology AI value will come from closed-loop follow-up. An actionable finding should start a pathway with a measurable end state: the follow-up exam is completed, the referral is completed, or the recommendation is clinically resolved with a documented rationale. The post The Last Mile Problem in AI Radiology: Detection Improves, Follow-Through…
HeartFlow, which makes AI tools to analyze cardiac images, sued its rival Cleerly, alleging infringement on six patents. Cleerly is pushing back. The post Heartflow Sues Cardiac AI Rival Cleerly Over Alleged IP Theft appeared first on MedCity News.
Vida Health is partnering with ŌURA to use data from the Oura Ring to provide more continuous, personalized cardiometabolic care and improve patient outcomes. The post Vida Health Teams Up with ŌURA to Provide More Personalized Metabolic Care appeared first on MedCity News.
Travere Therapeutics’ Filspari is now the first FDA-approved drug for focal segmental glomerulosclerosis (FSGS), a rare kidney disease. Analysts project the pill will become a blockbuster seller. The post Bouncing Back From Trial Failure, Travere Wins First FDA Approval in Rare Kidney Disease appeared first on MedCity News.
[Sponsored] 74% of healthcare AI is stuck in pilots. The reason isn’t the AI, it’s the data architecture underneath it. Read more to find the solution. The post 5 of the Top 10 U.S. Health Systems Are Moving to This New Health IT Category. Here’s Why. appeared first on MedCity News.
To address the clinical burden and enhance R&D, companies are turning to virtual solutions. This involves synthetic data, digital twin models, and AI to speed analysis. The post Why Synthetic Data is the Antidote to Clinical Trials appeared first on MedCity News.
The question is where will healthcare see the greatest value? Here are five use cases that define the greatest ROI for leveraging agentic AI for clinical supply chain operations. The post Clinical Supply Chain Hits Its AI Turning Point appeared first on MedCity News.
Hospitals are still on quite fragile financial footing if you look beneath the surface, according to new Kaufman Hall data. Rising costs, uneven patient volumes, and ongoing reimbursement and payer mix pressures continue to limit the sector’s financial recovery. The post Hospital Margins Squeeze as Costs Outpace Revenue Growth appeared first on MedCity News.
New research from the Elevance Health Public Policy Institute finds that higher enrollment in Medicare Advantage may be linked to lower overall Medicare spending. The post Report: Growth in MA Is Associated With Lower Total Medicare Spending appeared first on MedCity News.
Revolutions Medicines’ daraxonrasib met the main goals of its Phase 3 test in pancreatic cancer, posting results that were both statistically significant and clinically meaningful. The company now plans to file for speedy regulatory approval under a new FDA pilot program. The post Revolution Medicines Reports ‘Unprecedented’ Survival in Pivotal Pancreatic Cancer Trial appeared first…